Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump BioSpaceAn unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy...Read full story pharminent July 9, 2026 (Last updated: July 9, 2026) BioSpace An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy… Read full story Post navigation Previous: NICE aims to cut funding for Amgen lung cancer drug LumykrasNext: GSK ends dementia alliance with Alector after setbacks Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
